Quick Answer
Praxis Precision Medicines, Inc. reported Stockholders Equity of $878.14 million for fiscal year 2025.
Praxis Precision Medicines, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $878.14M | +97.1% |
| 2024 | $445.45M | +16.4% |
| 2024 | $382.67M | -8.7% |
| 2024 | $419.10M | +82.5% |
| 2024 | $229.68M | +229.7% |
| 2023 | $69.67M | -19.7% |
| 2023 | $86.76M | -17.9% |
| 2023 | $105.62M | +63.8% |
| 2023 | $64.47M | -15.3% |
| 2022 | $76.11M | -27.6% |
| 2022 | $105.16M | -24.3% |
| 2022 | $138.87M | -27.3% |
| 2022 | $191.02M | -23.8% |
| 2021 | $250.81M | -15.2% |
| 2021 | $295.92M | -11.3% |
| 2021 | $333.77M | +25.7% |
| 2021 | $265.51M | -7.6% |
| 2020 | $287.46M | +333.2% |
| 2020 | -$123.26M | -18.4% |
| 2020 | -$104.08M | -14.7% |
| 2020 | -$90.76M | -12.0% |
| 2019 | -$81.01M | -97.4% |
| 2018 | -$41.04M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $343.50M | -10.2% | -15.0% |
| June 30, 2025 | $404.22M | -3.5% | -8.0% |
| March 31, 2025 | $439.21M | +91.2% | -1.4% |
| December 31, 2024 | $445.45M | +539.4% | +16.4% |
| September 30, 2024 | $382.67M | +341.1% | -8.7% |
| June 30, 2024 | $419.10M | +296.8% | +82.5% |
| March 31, 2024 | $229.68M | +256.3% | +229.7% |
| December 31, 2023 | $69.67M | -8.5% | -19.7% |
- Praxis Precision Medicines, Inc. showed an increase of +97.1% in Stockholders Equity compared to the prior fiscal year.
- Over the 2018–2025 period, Praxis Precision Medicines, Inc.’s stockholders equity has grown by 2239.8% (from -$41.04 million to $878.14 million).
- The most recent figure is from Praxis Precision Medicines, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: